Drug Profile
Adalimumab biosimilar - Biocon
Alternative Names: BMO 2; MYL 1401ALatest Information Update: 16 Jan 2023
Price :
$50
*
At a glance
- Originator Biocon
- Developer Biocon; Mylan
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Rheumatoid arthritis
- Discontinued Plaque psoriasis
Most Recent Events
- 06 Jan 2023 Discontinued - Phase-III for Plaque psoriasis in Estonia, Ukraine, Hungary, Germany, Bulgaria, Russia, Poland (SC)
- 29 Nov 2022 Biocon acquires the global biosimilars business of Viatris
- 25 Sep 2020 No development reported - Phase-III for Plaque psoriasis in Estonia, Hungary, Germany, Bulgaria, Russia, Poland, Ukraine (SC)